Pediatric Liver Transplantation by Seu, Philip & Busuttil, Ronald W.
HPB Surgery, 1991, Vol. 3, pp. 145-166
Reprints available directly from the publisher
Photocopying permitted by license only
(C) 1991 Harwood Academic Publishers GmbH
Printed in the United Kingdom
PEDIATRIC LIVER TRANSPLANTATION
PHILIP SEU and RONALD W. BUSUTTIL
(Received 23 April 1990)
INTRODUCTION
Liver transplantation is the treatment of choice for various causes of end-stage liver
disease in children1. Remarkable progress has been made in the field since the first
human orthotopic liver transplant was performed in a child in 19632. The number of
transplants performed has increased especially since 1983, when liver transplan-
tation was given therapeutic status by the NIH consensus conference 1. By October
1986, five U.S. centers had performed more than 20 pediatric transplants each, but
in 1988 it is estimated that approximately 280 pediatric OLT’s were performed. The
majority are done in eight major centers and this concentration of experience is
necessary for continued optimal results.
This overview of the field will attempt to highlight aspects of liver transplantation
especially pertinent to pediatrics including childhood diseases, technical consider-
ations in children, and technical complications.
DISEASES TRANSPLANTED
The diseases in pediatric patients treated with OLT at UCLA are listed in Table 1.
Biliary atresia was the most common followed by inborn errors of metabolism, and
"cirrhosis" from various causes. This is consistent with reports from other institu-
tions with large pediatric OLT programs3.
BILIARY ATRESIA
This is the most common indication for liver transplantation in children as noted
above. Biliary atresia can be defined as a partial or complete absence of patent bile
ducts. The incidence varies from 1:8,000 to 1"10,000 with a 4-5 fold increase in
Pacific and Indian Ocean areas4. In approximately 2-3% of cases of extrahep,atic
biliary atresia(EHBA), surgical exploration reveals a dilated hilar structure which
may communicate with intrahepatic bile ducts, the so-called "correctable" type of
EHBA. Before 1959, the natural history of patients with "uncorrectable" biliary
atresia was progressive liver failure and death before age two months. In 1959, Kasai
and Suzuki devised the operation of hepatoenterostomy which consisted of using a
defunctionalized loop of jejunum to drain microscopic ducts within the porta
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Table 1 Pediatric liver transplants
Disease Patients transplanted Deaths
Biliary atresia
Biliary atresia 76 19
Biliary hypoplasia 2
Alagille’s syndrom 2
Nonsymptomatic paucity of intrahepatic bile ducts
Metabolic disorders
Alpha-l-antitrypsin deficiency 13 2
Tyrosinemia 2 1
Sanfilippo syndrome
Byler’s syndrome 1
Gaucher’s syndrome 1 1
Cirrhosis
Idiopathic cholestasis/cirrhosis 9
Familial cirrhosis 7 1
Chronic active hepatitis 7 2
Inflammatory
Acute hepatic necrosis 9 2
Subacute hepatic necrosis 1
Tumors
Hepatoblastoma 1 1
Hemangioendothelioma 1
Metastatic leiomyosarcoma 1
Hepatocellular carcinoma
Miscellaneous
Budd-Chiari syndrome
Total 137 30
hepatis5. Since then, numerous modifications of the procedure have occurred6. The
operation needs to be performed early in life, generally within four months.
Successful bile flow is achieved in 40-60% of patients operated on before age four
months7’8. Even with initially successful bile drainage, many patients will exper-
ience progressive cholestasis and cirrhosis, possibly due to an intrahepatic cause9.
The most common clinically identifiable cause of failure of an initially succesful
Kasai procedure is cholangitis1. Other causes of late failure include inadequately
sized periportal bile ducts and progression to fibrosis. Ninety percent of children in
whom a Kasai procedure fails to provide adequate permanent bile drainage will die
by age 5 years11. Reattempts at bile drainage after an initially unsuccessful Kasai
procedure have been uniformly poor12’13.
In a group of 31 patients transplanted for biliary atresia at Pittsburgh, early
survival was 84% (followup of 2-36 months) and prior biliary surgery did not
significantly affect survival after OLT12. In the UCLA experience reported in 1988,
28 of 36 patients who underwent OLT for biliary atresia had undergone prior
hepatic portoenterostomy. This group had no significant differences in intraopera-
tive blood loss, biliary complications or six month survival from the group without
prior Kasai procedures. The overall three year actuarial survival was 75%14. To
date, 76 patients have received OLT for biliary atresia at UCLA with an overall
survival of 75%.
In conclusion, children with biliary atresia should undergo early portoenteros-
tomy, but at the first Sign of failure should be referred for OLT evaluation.PEDIATRIC LIVER TRANSPLANTATION 147
INBORN ERRORS OF METABOLISM
Alpha-l-antitrypsin deficiency
This is the most common of the metabolic disorders for which OLT is performed.
Cirrhosis associated with ATT deficiency was first reported in 10 children in 196915.
Alpha-l-antitrypsin is one of several serine proteases synthesized in the liver which
inhibit a wide variety of proteolytic enzymes within plasma, including trypsin16. The
gene for the enzyme has 24 alleles with autosomal co-dominance. The Pi(protease
inhibitor) MM phenotype is normal. Most end-stage liver disease is associated with
the PiZZ phenotype and they usualy have between 10-15% of the normal serum
ATT level of 200-400mg/d117. They are also susceptible to emphysema which
generally develops in adults. The incidence of PiZZ among 200,000 infants screened
was 125(.06%). Of these, 14(11%) had neonatal cholestatic jaundice, and at age
two years, three of the 14(27%) progressed to cirrhosis. The overall development
of cirrhosis being 3 out of 200,000 infantsTM.
The pathogenesis of hepatic injury is felt to be due to either hepatocyte damage
by uninhibited proteolysis, and/or accumulation of ATT deposits within
hepatocytes19. Clinical cholestasis usually develops before ten weeks of age.
Neonatal cholestasis usually abates until late childhood or early adolescence when
cirrhosis and portal hypertension appear. The progression of cirrhosis and liver
failure is variable. The diagnosis should be considered in any neonate with
jaundice. Absent alpha-1 globulin peak in serum electrophoresis increases suspi-
cion and can be confirmed by low serum ATT activity, quantitative measures of
serum AT, and genetic Pi typing2. OLT is offered to patients with cirrhosis and
evidence of progressive hepatic decompensation. Following successful OLT, reci-
pients acquire the phenotype of the donor and ATT levels normalize21 and
progression of pulmonary disease is presumably eliminated by OLT. Five year
actuarial survival of children transplanted for ATT has been reported to be up to
greater than 80% 22.
Tyrosinemia
This is a hereditary disorder characterized by a deficiency of p-hydroxyphenol
pyruvate hydroxylase, an enzyme which degrades metabolic products of tyrosine
metabolism23. The hepatic disease ranges from early onset of acute hepatic failure
to slowly progressive cirrhosis. Patients also have a significantly increased incidence
of hepatocellular carcinoma. Four of nine patients in one series who successfully
underwent OLT for tyrosinemia had malignancy at the time of referral24.
Wilson’s Disease
Wilson’s disease is an autosomal recessive disorder characterized by accumulation
of copper in the liver, central nervous system, kidney, eyes, and other organs. The
prevalence in 1/30,000 worldwide with a carrier frequency of 1/9025. The metabolic
defect is in the excretion of copper from hepatocellular lysozymes which results in
accumulation and subsequent hepatic damage. When the hepatic capacity is
exceeded, copper diffuses into the blood and other organs. Characteristic
Kayser-Fleischer rings in patient’s corneas are copper deposits in Descement’s
membrane26.148 P. SEU and R. W. BUSUTTIL
The clinical course of hepatic manifestations is variable. It may have an insidious
onset of progressive hepatic insufficiency and resultant synthetic dysfunction and
portal hypertension, or the hepatic disease may be acute and self-limited, or it may
be fulminant. The fulminant form occurs most commonly in adolescent patients26.
The diagnosis is generally made by measuring low serum ceruloplasmin concen-
trations (< 20mg/dl.), with the presence of Kayser-Fleischer rings in the appropri-
ate clinical setting. Liver biopsy with quantitative copper measurements and
increased urinary copper excretion confirm the diagnosis26.
The initial treatment is copper chelation with d-penicillamine. If started before
irreversible tissue damage occurs, medical treatment is usually effective:7. In
contrast, such treatment is ineffective when cases present as fulminant or severe
subacute hepatitis. The fulminant form of Wilson’s disease usually differs from
other usual causes of fulminant hepatitis by the presence of a profound Coomb’s
negative tiemolytic anemia, moderate elevation of transaminases and alkaline
phosphatase levels while having a very high bilirubin and profound hepatic
failure:8.
The indications for OLT in Wilson’s disease include fulminant hepatitis, cirrho-
tics with hepatic decompensation who failed to improve with two to three months
of D-penicillamine treatment, and patients who have been effectively treated, then
fail after stopping the D-penicillamine26. Patients do well after successful OLT, and
plasma levels of coper and ceruloplasmin normalize3.
Crigler-Na]]ar Syndrome
This is a syndrome described in 1952 by Crigler and Najjar as "congenital familial
nonhemolytic jaundice’’29. It has been divided into Type I and Type II. Type I is
characterized by undetectable bilirubin glucuronyl transferase activity in liver tissue
and unresponsiveness to phenobarbital therapy. These patients progress to death
from kernicterus usually before age 15 months and should be considered early for
OLT. Type II disease, on the other hand, is less severe and often responds to
phenobarbital therapy.
Protoporphyria
This is an autosomal dominant disease characterized by elevated levels of protopor-
phyrin in erythrocytes, plasma and feces. The biochemical abnormality is in
deficiency of heme synthase (ferrochelatase) activity31. Photosensitivity is the main
clinical manifestation but progressive liver damage may occur due to hepatic
deposits of protoporphyrin crystals. Medical treatment of the disease is with
30 cholestyramine and OLT has successfully treated refractory cases3.
Other metabolic diseases treated with OLT include glycogen storage diseases,
hemochromatosis, enzymatic deficiency of the urea cycle, and homozygous type II
32 hyperlipoproteinemia
ACUTE FULMINANT LIVER FAILURE
This syndrome is defined as the development of liver necrosis and hepatic
encephalopathy within eight weeks of onset of symptoms in a patient without aPEDIATRIC LIVER TRANSPLANTATION 149
prior history of liver disease33. The etiologies are diverse and include viral hepatitis,
exposure to toxins, Wilson’s disease, Budd-Chiari syndrome, and pregnancy. The
clinical course is one of rapid deterioration of liver function and onset of neurologi-
cal failure often progressing to coma and death. The mortality rate is reported up to
60-85% despite maximal supportive medical treatment34’35’36. Liver transplantation
for fulminant liver failure was first performed in 1968 and since then, progressively
more have been done with an over 60% survival37.
In evaluating fulminant patients for OLT, a thorough neurological evaluation is
necessary to assess for reversibility of neurologic deficits. Nine pediatric patients
have been transplanted at UCLA for acute hepatic necrosis with a 78% current
survival.
BUDD-CHIARI SYNDROME
The Budd Chiari syndrome results from obstruction of the hepatic veins38.
Etiologies in the U.S. include hypercoagulable states secondary to various causes
including systemic lupus erythematous, polycythemia, and oral contraceptive use.
Mechanical causes include membranous obstruction or external compression from
malignancy.
Presentation is usually in a young person who develops rapid onset of abdominal
pain, ascites, and hepatomegaly which may be associated with liver failure. The
diagnosis is confirmed via hepatic venous and inferior vena caval angiography at
which time venous pressures should be measured.
Therapy is portosystemic shunting and anticoagulation if hepatic failure is not
present. A mesocaval H-graft is recommended unless a gradient exists in the vena
cava in which case a mesoatrial shunt is preferred39. OLT is offered if hepatic
failure is associated with the Budd-Chiari syndrome and a 71% 1 year survival has
been reported4. At UCLA, we have transplanted four females (average age 25
years) for Budd-Chiari with three patients currently alive. Post-transplant anticoa-
gulation is recommended if hypercoagulability is the underlying etiology. The
Cambridge group
41 however feel that it is difficult to distinguish Budd-Chiari
patients who are likely to develop rethrombosis and they report 16 patients with
liver failure and Budd-Chiari who were all routinely anticoagulated after OLT. No
recurrrent hepatic vein thrombosis occurred during a mean followup of 28 months.
The post-operative hemorrhagic complication rate was < 14% and none were
lethal. The overall three year survival was 88%.
CHRONIC ACTIVE HEPATITIS
Chronic active hepatitis (CAH) is a pathologic diagnosis in which there are chronic
inflammatory and fibrosing hepatic lesions that is often progressive to cirrhosis and
liver failureaz. Etiologies are varied and include viral hepatitis (A,B, or NANB), or
rarely hepatic injury from toxins, alcohol or "idiopathic" causes. Hepatitis B is the
most common cause and HbsAg is a marker of the disease. Patients with CAH and
cirrhosis develop the usual manifestations of end stage liver disease, and is one of
the more common indications for OLT. The issue of recurrent disease after OLT
for hepatitis B induced CAH is an important one. The presence of HBeAg150 P. SEU and R. W. BUSUTTIL
indicates viral replication and these patients may have an increased likelihood of
reinfection of the transplanted graft. The incidence of recurrent B antigen positivity
after OLT is reported to be between 50-100% 43’44. In a review of 31 patients
transplanted with hepatitis B at UCLA, 11 (35%) had clinical or pathologic
evidence of recurrent hepatitis. Among these 11, seven have died from the disease.
The mean time from OLT to death from recurrent hepatitis was 9.6 months. (range
5-19 months).
MALIGNANCY
Patients with tumors confined to the liver would appear to be excellent candidates
for OLT since they do not suffer from all the disabling manifestations of chronic
liver disease. Short term survival has beeen excellent in these patients, but
approximately 50% eventually die from recurrent disease45. Analysis of our
experience at UCLA reveal a five year actuarial survival of 62.3% for malignancies
excluding hepatocellular carcinoma (HCC), but 16.3% for HCC. Concerning
childhood malignancies, a pooled review of 12 children undergoing OLT for
hepatoblastoma in the U.S. showed that 50% were still alive at 24 to 70 months
after OLT without evidence of disease46. One-half of the deaths in the series were
from tumor recurrence. Besides a careful preoperative search for extrahepatic
spread in all cases, staging exploratory celiotomy is recommended for HCC.
Despite all efforts, instances of finding extrahepatic tumor at the time of recipient
hepatectomy is possible, and having a second recipient available is recommended.
PATIENT EVALUATION AND SELECTION
The proper selection of patients for transplantation is crucial to a liver transplant
program. A multidisciplinary approach is used and inpatient evaluation is per-
formed by a team that includes transplant surgeons, pediatric hepatologists,
nephrologists, psychiatrists, anesthesiologists and infectious disease specialists.
During the first 57 months of liver transplantation at UCLA, 225 children were
evaluated for OLT. Among these, 37% were less than 12 months of age and 60%
were females. Of those evaluated, 69% were accepted and placed on an active
waiting list for OLT. Indications for OLT was the presence of any of the following
without a contraindication:l) biliary atresia with failed portoenterostomy, 2)
metabolic liver disease or cirrhosis leading to liver failure as evidenced by bleeding
varices or synthetic dysfunction, 3) fulminant or subacute progressive hepatic
failure, 4) cholestatic disorders resulting in persistent jaundice, pruritis, fatigue,
growth retardation, or the inability to attend school, and 5) primary liver tumors
confined to the liver47.
Routine blood chemistries and various cultures are performed. In addition,
portal vein ultrasonography is used to assess patency. CT scanning is used to
evaluate for the presence of extrahepatic malignancy when the possibility exists.
Contraindications to OLT include systemic diseases not curable by OLT, irrevers-
ible neurologic changes, extrahepatic malignancy, or sepsis outside the biliary tract.
Patients are accepted or rejected as candidates by committee, and an assessment of
urgency is assigned. Donor to recipient matching is based on ABO status and size,
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.5 that of the recipient have been used. Transplantation across ABO barriers
have been done in urgent situations. (See ABO mismatched graft.)
TECHNICAL CONSIDERATIONS
The recipient hepatectomy is the most difficult part of the transplant procedure.
Prior operations especially in biliary atresia patients, coagulopathy, and portal
hypertension all contribute to the increased difficulty. Almost all children with
biliary atresia have undergone a portoenterostomy prior to coming to transplan-
tation. Many have had multiple attempted revisions and have dense scar tissue in
the operated field. In such patients dissection of the portal structures is begun with
the posterior aspect of the right lobe of the liver, in a previously unviolated plane.
The right hepatic lobe can be reflected away from the duodenum and transverse
colon, and the Roux-en-Y limb identified and traced to the hepatic hilum. Next,
access to the portal structures is gained by transecting the Roux-en-Y limb and
reflecting it.
After the portal structures are dissected, the supra- and infrahepatic vena cavae
are isolated. In contrast to adults in whom veno-venous bypass is routinely used,
infants and small children tolerate venous occlusion fairly well, and veno-venous
bypass is rarely needed. Before the native liver is removed, trial clamping of the
vena cava is performed. Some of the larger children will not tolerate the clamping
and require bypass. After the recipient hepatectomy is completed, perfect hemos-
tasis must be achieved in the hepatic fossa, and this requires reapproximation of the
open peritoneal surfaces over the bare area and both triangular ligaments.
The graft implantation in children is especially challenging due to the small
caliber and delicate nature of the anastomoses. The anastomoses are performed in
the following order: suprahepatic inferior vena cava, infrahepatic inferior vena
cava, portal vein, hepatic artery, and biliary system. The vena caval anastomosis is
performed with 4-0 or 5-0 polypropylene interrupted anterior row and running
posterior row. The interrupted sutures facilitate growth of the anastomosis. The
portal vein anastomosis is a running 6-0 or 7-0 polypropylene suture unless the
vessel is too small in which case interrupted sutures are used. The new graft is then
perfused with portal blood while the arterial anastomosis is performed. The
method of arterial reconstruction depends on the anatomy of the donor and
recipient and an adaptive intraoperative strategy is necessary. The source of inflow
must be adequate to avoid technical failure. The preferred reconstruction is an
aortic carrell patch of the donor to a branch patch
48 of the celiac aorta of the
recipient. A running 6-0 or 7-0 polypropylene suture is usually used. The biliary
reconstruction in children is usually a Roux-en-Y choledochojejunostomy over an
internal stent to a 40 cm defunctionalized limb of jejunum. If the duct is not
diseased and is of sufficient caliber, an end-to-end choledochocholedochostomy
over a T-tube is preferred, but rarely possible in the pediatric population. After the
graft is implanted, three closed suction drains are placed before closure of the
abdomen.
REDUCED-SIZE LIVER TRANSPLANTATION
The transplantation of part of a liver was initially done in heterotopic liver152 P. SEU and R. W. BUSUTTIL
transpslantation due to size constraints and first reported by Fortner49. With
increases in centers performing OLT, a shortage of smaller donors exists. The
attrition rate of pediatric patients on waiting lists is reported to be up to 25-30% 50.
At UCLA, the figure is 10% and usually death is due to lack of a suitable donor.
Orthotopic transplantation of a reduced-size graft was initially reported by Bismuth
in Europe where the shortage of organs is even greater than in the U.S51. Recently,
Broelsch reported his experience with 14 children who received reduced liver
grafts5:. Thirteen of the 14 were urgent cases. These included three right lobe
grafts, nine left lobes, and two left lateral segments. Patient survival was 50%
which the authors felt were comparable to similar high-risk recipients of full-sized
grafts. The graft related and extrahepatic complication rates were 71% and 93%,
respectively, in the 14 patients. Guidelines by Broelsch include two independent
surgical teams when performing reduced-liver transplantation, use of donors up to
4-6 recipient weight, and determination of which lobe to use after opening the
recipient’s abdomen.
The largest experience to date with reduced-size grafting was reported by Otte, et
a153. They report 54 reduced-size grafts of which 30 were performed electively. The
overall one year patient survival was 82% for full grafts vs. 68% for reduced-sized
grafts. The one year survival of the 30 children who "electively" received reduced
grafts was 77%.
The complication rates after reduced-size grafting remains higher than that of
full-size grafts, but reduced-liver transplantation should be considered in emerg-
ency situations when a size-matched donor is not available, and the surgeon has the
necessary technical experience.
LIVER PRESERVATION
One of the more exciting recent developments in liver transplantation has been that
of extended liver preservation using a solution developed by Belzer at the
University of Wisconsin.(UW solution) Initial clinical trials demonstrated good
function in 17 livers stored in UW. In 9 of these, mean preservation times was 12.7
hours (range 11-20)54. The solution evolved from Belzer’s earlier work when he
showed the importance of phosphate and adenosine in kidney preservation55. In
addition to these compounds, UW solution contains unique polymer sugars
(hydroxyethyl starch, lactobionate) as nonionic osmotic agents, as well as glutath-
ione and allopurinol as antioxidants and oxygen free radical scavengers.
At UCLA we started using UW solution for liver preservation in May of 1988.
This has permitted significantly longer preservation times without compromise of
graft function. It is felt that the ability to lengthen preservation times will help
change the nature of liver transplantation practice as it permits greater flexibility in
utilization of operating room time and resources. Also the timing of donor and
recipient operation is not as critical, and this permits improved utilization of
available donor organs.
COMPLICATIONS
The complications of orthotopic liver transplantation to be discussed are outlined
on Table 2. They have been somewhat arbitrarily divided into "hepatic" and
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Table 2 Complications of orthotopic liver transplantation
Hepatic
A Technical
1 Harvest injuries
2 Arterial
hepatic artery thrombosis
pseudoaneurysms
3 Venous
hypoplasia/absence
thrombosis
4 Biliary
leak
obstruction
B Nontechnical
1 Primary nonfunction
2 Rejection
acute
chronic
3 Mismatched graft
II Nonhepatic
A Infection
B Renal
hepatorenal
2 acute tubular necrosis
3 drug toxicity
4 dialysis
C Gastrointestinal
bleeding
2 perforation
3 obstruction
4 pancreatitis
D Pulmonary
1 atelectasis
2 effusion
3 respiratory failure/ARDS
4 infection
E Neurological
1 seizures
2 hemorrhage
3 positioning injuries
F Drug toxicity
HARVEST COMPLICATIONS
Technical harvest complications include injury to unrecognized aberrant right or
left hepatic arteries, liver laceration, or bowel injury. With multiorgan harvests
from the same donor, instances of cutting the suprahepatic vena cava too short for
optimal liver implantation have occurred. Other complications include hemodyna-
mically unstable donors and unrecognized pre-existing disease in the donor liver.
The consequences of these complications have ranged from the need to repair an
injury to cancellation of a transplant operation.
HEPATIC ARTERY THROMBOSIS
This is one of the most devastating complications following OLT. The incidence of
hepatic artery thrombosis (HAT) is significantly higher in pediatric series with rates
of 7.4-33% reported56’57’58.
The presentation of hepatic artery thrombosis can be categorized into 3 general
syndromes58. 1.) The first is that of fulminant hepatic necrosis and sepsis. Patients
develop rapid onset of hepatic decompensation and sepsis with fever, altered
mental status, hypotension, and coagulopathy. Laboratory studies reveal markedly
elevated liver enzymes, leukocytosis and prolonged protimes. Blood cultures are
frequently positive for gram negative enterics and also anaerobes. Radiographs
may show gas gangrene of the liver. 2.) The second presentation is that of relapsing
bacteremia frequently with hepatic abscesses. Patients develop fever, mild
increases in liver enzymes, leukocytosis, and positive blood cultures. 3.) The third
syndrome is that of biliary complications, like bile leaks, cholangitis, and strictures154 P. SEU and R. W. BUSUTTIL
causing obstruction. This picture results because the only arterial supply to the
allograft’s biliary tree is via the hepatic artery59.
In making the diagnosis of hepatic artery thrombosis, doppler studies have been
found to be effective screening studies with a high sensitivity6. False negatives do
occur and angiogram is frequently needed for confirmation.
At increased risk are small pediatric patients and those requiring complex
arterial reconstructions such as double donor arteries and iliac and aortic conduits.
In one series of patients
58 double donor arteries had a 24.1% incidence of arterial
thrombosis and iliac and aortic conduits had thrombosis rates of 27.7 and 23.1%
respectively. Mazzaferro
61 studied 28 variables in pediatric patients and identified
five that significantly affected the thrombosis rate. These were diameter <3mm,
number of revisions, use of iliac and aortic conduits, intraoperative administration
of fresh frozen plasma, and post operative anticoagulation.
In our pediatric series, we have had 17 cases of hepatic arterial thrombosis in 16
patients among 123 operations (14%). Because of the variable anatomy, several
methods of reconstruction have been employed, and an adaptive strategy is
necessary. Our preference is for an aortic Carrel patch to a "branch patch" of the
celiac axis of the recipient. Use of the supraceliac aorta of the recipient and
avoidance of the infrarenal aorta is also important. Prophylactic use of dextran
folowed by aspirin is recommended.
Retransplantation was necessary in 75% of our patients with hepatic artery
thrombosis. The indications for retransplantation are acute fulminant hepatic
gangrene, inability to control sepsis with antibiotics and drainage, and recurrent
cholangitis secondary to strictures. Twenty-five percent of patients with HAT are
being managed on chronic antibiotics. Hepatic artery thrombosis remains a
dreaded complication with mortalities as high as 50% reported58.
PSEUDOANEURYSMS
This is an extremely rare complication of OLT. In a report of eleven pseudoaneur-
ysms, five were nonanastomotic with three of these being related to infection. They
were mostly found incidentally on imaging studies, though they may present with
rupture, hemobilia or as an enteric fistula. Operative correction is needed because
of the high risk of significant complications62.
VENOUS COMPLICATIONS
The incidence of portal vein or inferior vena cava thrombosis is much lower than
that of arterial thrombosis with rates less than 2% reported63. We have had no cases
of venous thrombosis at UCLA. The presentation of venous thrombosis depends
on the timing of occurrence. Portal vein thrombosis early in the postoperative
course presents with severe allograft dysfunction and variceal bleeding if they were
preexisting. In cases of late thrombosis, venous collateral have usually developed
so that usually there are few allograft problems, and these patients develop varices,
ascites and splenomegaly. Similarly, acute caval thrombosis presents with allograft
dysfunction, but chronic cases develop insidious onset of ascites, edema, andPEDIATRIC LIVER TRANSPLANTATION 155
hepatomegaly. Various imaging studies have been utilized. Hepatobiliary scans
generally show delayed excretion in cases of venous thrombosis. Doppler studies
are good initial screening tests but have false negatives; angiograms are definitive.
Magnetic resonance imaging holds promise, but more experience is needed64.
One of the major risk factors is pre-existing venous abnormalities in the
recipient, and ultrasound to confirm portal vein patency is an important part of a
potential recipient’s evaluation. In a series of 313 OLT’s65, 16.3% had portal vein,
and 2.9% had vena caval abnormalities. The most common was portal vein
thrombosis especially in patients who had portosystemic shunts or the Budd Chiari
syndrome. Hypoplasia of the portal vein was a finding in some biliary atresia
patients with prior portoenterostomies. This has been reported to cause involution
of the portal vein65. Intraoperative adjustments needed include thrombectomy
and/or dissection to the confluence of the splenic and superior mesenteric veins and
use of a free graft from the confluence. Caval abnormalities reported include absent
retrohepatic cavae in biliary atresia and thrombosis in Budd-Chiari patients. Other
contributing factors may be a steal from a large coronary vein shunt and technically
imperfect anastomoses.
Treatment of acute portal vein thrombosis include thrombectomy, interposition
or jump grafts, or possibly retransplantation if severe graft damaage has occurred.
Late thrombosis is treated with portosystemic shunting and/or sclerosis of varices.
Patients transplanted for the Budd Chiari syndrome should generally be placed on
long term anticoagulation, especially if hypercoagulopathy was the etiology41.
BILIARY COMPLICATIONS
Biliary complications used to be the most common and lethal complication
following orthotopic liver transplantation, and was considered the "achilles heel" of
liver transplantation66. With increasing experience and standardization of recon-
structions, results have improved significantly. Recent series report biliary tract
complications in pediatric patients at 7-20% 56,67.
In adults, biliary leakage is the most common complication, and the most
common site is at the T-tube exit site68. In children, use of T-tubes are rare and
leakage is commonly from the choledochojejunostomy. Presentation is that of
fever, abdominal pain, elevated bilirubin and hepatic enzymes, and increased drain
output. Diagnosis can be confirmed by transhepatic cholangiogram or ERCP if
necessary. Treatment is antibiotic coverage and either simple surgical repair or
revision of the anastomosis. Contributing factors to biliary leaks are technical
errors at the anastomosis, ischemia from using a too long segment of donor duct,
6
and hepatic artery thrombosis. In our pediatric patients, eight developed biliary
leaks, of which five required simple closure and three needed revision of the
anastomosis.
Obstruction is the other major biliary complication. The presentation varies from
acute cholangitis and liver dysfunction, to recurrent mild fevers and elevated
enzymes, to progressive deterioration of allograft function. Etiologies include
anastomotic or intrahepatic strictures, T-tube or stent obstruction, stones or
recurrent disease like sclerosing cholangitis or cholangiocarcinoma. Diagnosis is
confirmed with cholangiogram, or ERCP. Treatment varies with the pathology.156 P. SEU and R. W. BUSUTTIL
Percutaneous dilatation of a localized stricture has been successful69, but sometimes
operative intervention like revision of a Roux-en-Y, or in cases of multiple
intrahepatic strictures, retransplantation may be required.
NONTECHNICAL HEPATIC COMPLICATIONS
Primary Nonfunction
This occurs when the transplantated hepatic graft, with intact arterial, venous and
biliary anastomoses never demonstrates evidence of initial function. The incidence
is reported to be between 5--10% 70’71. The result is a transplanted patient who
demonstrates frank hepatic failure with coma, acidosis, massive coagulopathy,
renal failure, hypoglycemia and shock. Lab studies confirm the clinical picture, and
biopsy reveals profound hepatic necrosis. Patient survival depends on successful
retransplantation. Possible causes include an ischemic/preservation injury to the
allograft, immunologic injury, or preexisting disease in the donor liver.
REJECTION
Rejection is the most common cause of allograft dysfunction and indication for
retransplantation68. It can be classified into acute and chronic rejection. Acute
rejection is much more common with mild acute rejection occurring in up to 80% of
hepatic allografts. More severe forms occur in 50-75%. The incidence of chronic
rejection is generally less than 5%
44
The presentation of acute rejection is that of fever, abdominal pain, decreased
bile production, elevated hepatic enzymes, and decreased synthetic function. More
severe cases, or untreated episodes can progress to frank hepatic failure with
neurologic and hemodynamic compromise. This presentation is nonspecific and
may also be due to technical problems, or various infections.
With no one absolute diagnostic test, the diagnosis is largely clinical and one of
exclusion. Acute rejection rarely occurs within the first transplant week. Especially
early post-transplant, one must rule out hepatic artery and venous thrombosis with
doppler studies. Hepatobiliary scans reflect hepatic function and adequacy of
biliary excretion. A thorough workup for infection is also necessary. Frequent use
of percutaneous hepatic biopsy is encouraged. It has been shown to be an
extremely safe procedure in experienced hands72 but is not always diagnostic.
Findings on biopsy in acute rejection range from mild portal inflammatory
73 infiltrates to severe hepatocyte destruction Chronic rejection is characterized by
the "vanishing bile duct syndrome ’’74. The treatment of rejection is discussed under
immunosuppression.
MISMATCHED GRAFTS
Potential liver donors are matched for size and ABO compatibility. Pre-transplant
screening for cytotoxic antibodies are not used clinically. ABO group compatibility
is desirable in OLT but not essential for succesful transplantation. Experience atPEDIATRIC LIVER TRANSPLANTATION 157
Pittsburgh
75 and UCLA
44 have demonstrated that results are significantly better in
ABO identical grafts vs. ABO nonidentical but compatible grafts, and worst in
ABO incompatible grafts. In our pediatric experience 82 ABO identical grafts
yielded a survival of 96% while 16 nonidentical but compatible and five incompat-
ible grafts survived 55 and 65% respectively. The use of nonidentical grafts should
be reserved for critical situations when no other donor is available.
NONHEPATIC COMPLICATIONS
Infection
Besides undergoing an extensive surgical procedure, these patients are greatly
immunosuppressed, and this combination can expect to yield frequent infectious
complications. Major centers have reported infections in 50-80% of patients44’76.
All classes of organisms are involved with a disproportionately high incidence of
viral infections. Kusne, et alTM reported the infectious complications in 101 consecu-
tive OLT patients. Of these, the overall infection rate was 83% and the percent of
patients with bacterial, viral, fungal, and protozoal infections were 59, 53, 18, and
12%, respectively. Important measures include the judicious use of prophylactic
antimicrobial agents, frequent surveillance, and aggressive treatment of diagnosed
infections.
Prophylactic regimes vary from institutions. At UCLA our prophylactic drugs
include broad-spectrum intravenous peri-operative antibiotics for 48 hours, bowel
preparation with neomycin and erythromycin base as well as mechanical enemas,
and oral nystatin. In patients with biliary atresia and multiple prior abdominal
operations, prophylactic amphotericin is used.
Viral infections commonly seen include CMV, HSV and EBV. CMV infections
can be serious and a primary cause of mortality. The differentiation from allograft
rejection can be difficult as both can present with fever, and elevation in liver
enzymes. Patients with CMV hepatitis have been treated and even retransplanted
for presumed rejection with fatal results77. The liberal use of percutaneous liver
biopsies and early treatment is essential. At UCLA we have treated 19 patients
with CMV infection with DHPG (gancyclovir) with success in 13.
Risk factors for serious bacterial and fungal infections in liver transplant patients
include prolonged intubation and complications related to the hepatic artery or
biliary tract. Common severe bacterial infections include intra-abdominal abs-
cesses, pneumonia and cholangitis. Fungal infections have been reported in
pediatric patients at a rate of 27-40% 78,53, with the most common organism being
candida.
The presence of infections is common in patients dying after OLT. Though a
unique cause of death cannot always be established, 13 of 21 of our pediatric deaths
had infection as a major contributing factor.
RENAL COMPLICATIONS
Varying degrees of renal insufficiency are common in liver transplant patients.
Many have renal failure pre-transplant from the hepatorenal syndrome.158 P. SEU and R. W. BUSUTTIL
Post-operative oliguria may be due to hypovolemia, intraoperative hypotension
and ATN, sepsis, or nephrotoxic drugs like cyclosporine, aminoglycosides or
amphotericin. A study of renal function in our pediatric patients who have been on
CsA over one year showed that 85% of the patients had true glomerular filtration
rates less than the low normal for age (90cc/min/1.73m2), and there was evidence of
progression of impairment with prolonged CsA USe79. Adequate support of a
patient’s renal perfusion with volume replacement, and close monitoring of CsA
levels are important measures. Patients with severe renalfailure may be taken off
CsA and immunosuppressed with OKT3.
Volume overload can be managed with use of diuretics, ultrafiltration, or
hemodia!ysis. The need for dialysis has a poor prognosis and the mortality rate of
OLT patients requiring dialysis is 40-70%8.
GASTROINTESTINAL COMPLICATIONS
Abdominal bleeding manifests with increasing abdominal girth and output from
drains. At reoperation, frequently no specific site is found and diffuse oozing is
often secondary to coagulopathyTM. Specific sites may be at vascular anastomoses or
the jejunojejunostomy. Other causes of bleeding may be due to stress ulcers or
gastritis, varices, herpes esophagitis, or CMV or candida colitis. Endoscopy and
biopsies are usually needed for diagnosis. Variceal bleeding after OLT should
prompt studies to rule out portal vein thrombosis.
Gastrointestinal perforation occurring early after OLT is frequently due to
unrecognized intra-operative injury. Th_e frequency is much higher in patients who
have had previous intraabdominal surgery and adhesions. Injuries like denuded
serosa and small electrocautery burns can progress to full thickness perforation.
Gastrointestinal leaks at the jejunojejunostomy can also occur due to technical
errors. Patients present with intraabdominal sepsis and free intra-abdominal air,
and operative repair is necessary. Late perforation is less common and etiologies
include perforation secondary to lymphoproliferative disease81 or infectious ulcers.
GI obstruction is usually due to post-operative adhesions. Rarer causes include
herniation of the jejunojejunostomy or lymphoproliferative diseases.
Mild transient hyperamylasia is common in OLT patients and usually no
treatment is necessary. Significant pancreatitis is rare. Patients at increased risk are
those who have undergone extensive peripancreatic dissection like with portal vein
grafts, and one study found an increased incidence in HBsAg + patients82.
PULMONARY COMPLICATIONS
Some form of pulmonary morbidity occurs in essentially all liver transplant
recipients. Atelectasis, effusions, and infection are the most common. Atelectasis
usually resolves with aggressive pulmonary toilet and as patients get more ambula-
tory. Twenty percent required bronchoscopy in one seriesTM. Right pleural effusions
are also very common and usually resolve over time. Thoracentesis or thoracos-
tomy is necessary in 15-20% of patients due to large symptomatic effusions or
suspicion of infection. Paralysis of the right hemidiaphragm is seen after OLT and
is felt to be due to an intra-operative injury to the phrenic nerve when the superior
vena caval clamp is applied.PEDIATRIC LIVER TRANSPLANTATION 159
NEUROLOGIC COMPLICATIONS
One of the more common complications after OLT is seizures. The incidence is up
to 20%44. Many are related to high CsA and low magnesium levels. Patients usually
have normal CT scans and lumbar punctures and recover without residual deficits.
Other complications include meningitis, extrapyralaidyl symptoms, and pares-
thesias. Positioning injuries like brachial plexus and peroneal nerve injuries are
also seen. Intracranial hemorrhage occurs in patients with severe liver failure and
is a frequent lethal event in these patients.
IMMUNOSUPPRESSION
Improvements in our ability to prevent and treat rejection is a critical factor in the
development and success of solid organ transplantation. Experience with many of
the drugs in use was initially gained in human kidney transplantation. In the early
1960’s, the use of azathioprine opened the way for the development of clinical
organ transplantation. The early liver transplants received double-drug therapy
with azathioprine and corticosteroids with limited success. In the mid-1960’s,
results improved somewhat when triple-drug therapy was introduced with the
addition of antilymphocyte globulin (ALG). The most dramatic improvements
occurred with the clinical use of cyclos,porine A in the early 1980’s which introduced
a new era in organ transplantation s3. Currently, we utilize glucocorticoids, azathio-
prine, CsA, and the monoclonal anti-T cell antibody OKT3.
GLUCOCORTICOIDS
Glucocorticoids have been an essential part of transplant immunosuppression.
They are used universally in induction therapy in combination with other drugs,
and also for the treatment of allograft rejection. Steroids have multiple anti-
inflammatory and immunologic effects that have been described extensively. The
mechanism by which glucocorticoids inhibit allograft rejection is by the inhibition
of interleukin I and interleukin II, and therefore the stimulation of cytotoxic
T-cells84.
Side effects are well known and include increased susceptibility to infection,
growth retardation, gastrointestinal ulcers, fluid retention, truncal obesity and
osteoporosis. The dose of steroids has been able to be decreased with multiple drug
regimens in attempts to minimize the toxicities.
AZATHIOPRINE
Azathioprine or imuran is used in induction therapy with steroids and CsA. It is a
derivative of 6-mercaptopurine and functions as an antimetabolite of purine
synthesis. It therefore is most effective against rapidly dividing cells85. Azathioprine
dosing is between 1-4 mg/kg/day. Major side effects are neutropenia and thrombo-
cytopenia which may limit its use in some casess6. Other toxicities include increased
risk of infection, anemia, and possibly pancreatitis and hepatitis.160 P. SEU and R. W. BUSUTTIL
CYCLOSPORINE A
The introduction of CsA into clinical transplantation has revolutionized the field. It
is a much more useful drug than any of its precursors due to its potent immunosup-
pressive actions and relatively less toxicities. CsA works by interfering with the
action of interleukin 2 which consequently blocks activation of cytotoxic T cells
while T suppressor cells continue to function 87. It is a lipophyllic drug that can be
administered orally or intravenously. It is metabolized by the hepatic P450 enzyme
system, and other drugs which affect the P450 enzymes will influence CsA
metabolism. CsA levels are monitored via high pressure liquid chromatography
(HPLC) techniques which measures levels of only the parent compound, or less
specific radioimmunoassay (RIA) tests which measure the less active metabolites
also.
CsA is far from being the ideal immunosuppressantdue to its toxicities. The most
important of these is its nephrotoxicity. It is often reversible, but long lasting
impairment also occurs (see Renal Failure). It is important to establish adequate
urine output post-OLT before administering CsA, and carefully monitoring levels.
Other side effects include hepatotoxicity with hyperbilirubinemia, hypertension,
sodium and fluid retention, magnesium wasting, seizures, and hirsutism.
OKT3
OKT3 is a murine monoclonal antibody that binds to the T3 protein located on the
surface of all peripheral T cells88. This binding blocks the activation of the T cells
and also facilitates opsonization of the bound cells. It was first shown to be
effective in reversing acute renal allograft rejection
9 and since then has been used
in liver transplantation. The UCLA experience with using OKT3 to treat steroid-
resistant rejection was reported in 19879. In our pediatric patients, OKT3 has been
used to treat 43 episodes of steroid-resistant rejection in 31 patients with a 79%
success rate. Dosing of OKT3 is adjusted by measuring CD3 + cells in peripheral
blood.
Toxicities of OKT3 include increased risk of infections, especially viral, pulmon-
ary edema, flu-like reactions with fever and chills and a meningitis syndrome.
Premedication with steroids and acetaminophen for the initial doses helps decrease
the flu-like reactions. One should also assure that the patient is clinically euvolemic
with a clear chest X-ray to decrease the risk of pulmonary edema which can be
lethal. If necessary, patients should be diuresed or dialyzed before the initial dose.
FK 506
FK506 is a recently introduced macrolide compound isolated in Japan from a soil
fungus, Streptomyces tsukubanesis that has been shown to have potent immunosup-
pressive effects91. Its exact mechanism of action has not been completely eluci-
dated, but it appears to share similarities with cyclosporine A in that a major effect
of both is inhibition of interleukin 2 (IL2) production. However, FK 506 is up to
100x more potent in inhibiting IL2 mRNA production in activated human
peripheral blood T-cells than cyclosporine92.PEDIATRIC LIVER TRANSPLANTATION 161
The potent immunosuppressive effects of FK506 have been confirmed in various
animal models including rat heart allografts, kidney and liver transplants in
dogs93’94, as well as kidney transplants in baboons95. Much excitement has been
generated about the use of FK506 clinically because of its remarkable potency at
low doses and apparant lack of significant toxicities. Initial human trials have begun
and a large multicenter trial will start shortly.
CURRENT UCLA IMMUNOSUPPRESSION PROTOCOL
Induction Therapy
We employ triple-drug therapy with steroids, cyclosporine A, and azathioprine.
Methylprednisolone is started intravenously at the time of transplant at 20-30mg/
kg and rapidly tapered to .3-5mg/kg/day over the first week. When oral intake
resumes, the steroids are given as oral prednisone at an equivalent dose.
The first CsA dose is given pre-operatively at 15mg/kg orally. The post-operative
doses are started after adequate urine output is established at 3-5mg/kg/day
intravenously in two divided doses. Each dose is infused over four hours. The dose
is adjusted daily based on CsA trough plasma levels with a target range of 200-
300ng/ml. After oral intake is established, oral CsA is started at 10-15mg/kg/day in
two divided doses. The intravenous dose is continued and tapered as therapeutic
levels are reached with the oral dose. The overlap is usually 5-7 days. In cases of
renal insufficiency, CsA doses are decreased accordingly or even held as indicated.
Azathioprine is started at 1-2mg/kg/day intravenously on the first post-transplant
day and later converted to the same oral dose. It is held in cases of neutropenia or
severe sepsis.
MAINTENANCE IMMUNOSUPPRESSION
Again, triple-drug therapy is used in most patients. Prednisone is tapered gradually
and maintained on as low a dose as possible. Cyclosporine doses are adjusted so
that higher levels are maintained early after OLT but allowed to drop to the 140-
160ng/ml range in stable patients greater than one year after OLT. In patients with
stable levels and renal function, levels are checked about every two months.
Azathioprine is maintained at lmg/kg/day.
TREATMENT OF REJECTION
Patients diagnosed with rejection are initially treated with intravenous methylpred-
nisolone at 20mg/kg with tapering over five days to the pre-treatment dose. Patients
not responding or having recurrent rejection are generally rebolused if no other
cause of allograft dysfunction is apparent. Patients felt to have steroid-resistant
rejection are currently treated with OKT3. The intravenous dose is 2.5mg for
children <30kg. or 5mg for those > 30kg. A typical treatment course lasts 10-14
days. If peripheral T3+ cells exceeds 10%, the dose of OKT3 is increased.
Persistent refractory rejection is either treated with antilymphocyte globulin or
retransplantation.162 P. SEU and R. W. BUSUTTIL
RESULTS
The survival of pediatric patients after OLT has shown progressive improvement
over time. Major factors have been improved immunosuppression especially with
cyclosporine, refinement of operative techniques and increasing technical exper-
ience, earlier referral and selection of patients for OLT, and improvements in
perioperative management. One year survival prior to 1980 were 30-40%, but with
the above mentioned improvements, current pediatric survival rates exceed 70% in
most centers. Recent pediatric series report two and three year survivals of 8696 and
73% TM. The five year actuarial survival curve for the first 123 pediatric OLTs
performed at UCLA is shown in Figure 1. The overall 5 year survival is 77%. The
prognosis is better for metabolic diseases than tumors or biliary atresia. The
majority of deaths occurred within 5 months, so the survival curves can be expected
to be maintained.
Besides survival, the success of a procedure on children depends on the
successful growth and development of the transplant recipients. Multiple reports
have documented the satisfactory physical and intellectual development in the
majority of patients. In a UCLA study of 19 patients, 16 exhibited normal or
accelerated growth after transplantation97. In the Pittsburgh pediatric series
reported in 198798 50% achieved accelerated growth, and 45 of 57 children were in
an age-appropriate school grade or only one year behind. Essentially all our current
school aged survivors are able to attend school.
%
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FIGURE 1. Actuarial survival curves by diagnosis. Overall 5-year
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CONCLUSION
Liver transplantation is able to cure children with end-stage diseases with accep-
table morbidity and mortality, and improve their quality of life. Results can expect
to improve with greater availability of donor organs, earlier referral of candidates
to transplant centers, further technical refinements, and the development of more
specific, less toxic immunosuppressive agents.
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